Apr 23, 2024, 2:51 PM
Apr 23, 2024, 6:04 AM
Novartis exceeds Q1 drug sales targets and raises full-year guidance
- Novartis reported better-than-expected first-quarter earnings.
- The company raised its full-year guidance after strong sales of heart failure and psoriasis treatment drugs.
- Investors responded positively, with shares climbing 4.8% in early trading.
Opinions
You've reached the end